HANGZHOU - WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that three sets of 5,000L single-use bioreactors have been successfully installed in the second drug substance line at its drug substance manufacturing facility in Hangzhou ('MFG20'), which became operational in 2021.
With the GMP production of the newly installed bioreactors, the total capacity of the facility is to be increased from 8,000L to 23,000L, which will further enhance the company's manufacturing capability for global clients.
Compared with stainless steel bioreactors, single-use bioreactors allow for highly flexible and cost-effective manufacturing, and are more environmentally sustainable with reduced contamination risk. The larger reactor size improves manufacturing efficiency by lowering the number of production batches and decreases production cost by reducing equipment, labour, and material consumption. Single-use technologies are widely adopted across WuXi Biologics' global manufacturing network, at scales ranging from 200L to 4,000L. The new 5,000L single-use bioreactors at MFG20 are expected to complete GMP release later this year.
Dr. Chris Chen, CEO of WuXi Biologics, commented, 'The addition of 5,000L single-use bioreactors is a major milestone in our company's offerings, as we enhance capacity and capability to meet the needs of our clients. As a leader in utilizing single-use technologies to accelerate biological manufacturing, WuXi Biologics is constantly exploring industry best practices and implementing innovative solutions to offer our clients more flexible, cost-effective, and sustainable services, advancing their therapies for patients worldwide.'
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics - from concept to commercialization - for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2023, WuXi Biologics is supporting 698 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to be an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
Contact:
Email: info@wuxibiologics.com
Email: PR@wuxibiologics.com
WUXI BIOLOGICS (CAYMAN) INC. 
